A common carcinogen benzo[a]pyrene causes neuronal death in mouse via microglial activation by Dutta, Kallol et al.
A Common Carcinogen Benzo[a]pyrene Causes Neuronal
Death in Mouse via Microglial Activation
Kallol Dutta., Debapriya Ghosh.¤, Arshed Nazmi, Kanhaiya Lal Kumawat, Anirban Basu*
National Brain Research Centre, Manesar, Haryana, India
Abstract
Background: Benzo[a]pyrene (B[a]P) belongs to a class of polycyclic aromatic hydrocarbons that serve as micropollutants in
the environment. B[a]P has been reported as a probable carcinogen in humans. Exposure to B[a]P can take place by
ingestion of contaminated (especially grilled, roasted or smoked) food or water, or inhalation of polluted air. There are
reports available that also suggests neurotoxicity as a result of B[a]P exposure, but the exact mechanism of action is
unknown.
Methodology/Principal Findings: Using neuroblastoma cell line and primary cortical neuron culture, we demonstrated that
B[a]P has no direct neurotoxic effect. We utilized both in vivo and in vitro systems to demonstrate that B[a]P causes
microglial activation. Using microglial cell line and primary microglial culture, we showed for the first time that B[a]P
administration results in elevation of reactive oxygen species within the microglia thereby causing depression of antioxidant
protein levels; enhanced expression of inducible nitric oxide synthase, that results in increased production of NO from the
cells. Synthesis and secretion of proinflammatory cytokines were also elevated within the microglia, possibly via the
p38MAP kinase pathway. All these factors contributed to bystander death of neurons, in vitro. When administered to
animals, B[a]P was found to cause microglial activation and astrogliosis in the brain with subsequent increase in
proinflammatory cytokine levels.
Conclusions/Significance: Contrary to earlier published reports we found that B[a]P has no direct neurotoxic activity.
However, it kills neurons in a bystander mechanism by activating the immune cells of the brain viz the microglia. For the first
time, we have provided conclusive evidence regarding the mechanism by which the micropollutant B[a]P may actually
cause damage to the central nervous system. In today’s perspective, where rising pollution levels globally are a matter of
grave concern, our study throws light on other health hazards that such pollutants may exert.
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Introduction
Benzo[a]pyrene (B[a]P), is a member of the polycyclic aromatic
hydrocarbon (PAH) family that contains about 100 different
chemicals; B[a]P being the most studied member of that family
[1]. Owing to its relatively high environmental levels and high
level of toxicity that results in larger health impact than any other
PAH identified in the environment, B[a]P is often considered as a
surrogate for other PAH compounds.
B[a]P is released into the environment (air, water and soil) from
natural sources such as volcanoes, forest fires and from man-made
sources including industrial and automobile exhaust fumes [2],
manufacturing of products such as coal, tar, asphalt [3], petroleum,
cigarette smoke [4,5,6] and charcoal-broiled, fried, roasted and
smoked foods [7,8,9]. PAH levels in soil have been found to be higher
in urban setup when compared to rural environment, due to
vehicular traffic [10]. The general population is exposed to B[a]P on
a daily basis (Table 1), mainly via ingestion of contaminated foods,
water and inhalation of polluted air [11,12,13]. Lioy et. al. reported in
1988 that the estimated B[a]P intake ranges from 20 to 800 ng per
day in people living in the vicinity of hazardous waste sites
contaminated by PAHs [14]. In 1991, Hattemer-Frey and Travis
reported that the long-term average daily intake of B[a]P by the
general population of the United States is estimated to be 2.2 mg per
day [15]. The food ingestion pathway of accumulating PAHs such as
B[a]P has been shown to be up to ten times higher in magnitude than
risks determined from exposures due to other pathways such as soil
contamination [16]. Cooked meat products have been shown to
contain up to 4 ng/g of B[a]P [17], and up to 5.5 ng/g in fried
chicken [18] and 62.6 ng/g in overcooked charcoal barbecued beef
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[19]. Fats and oils are also considered as one of the major sources of
PAHs like B[a]P in the diet because of their lipophilic nature
[20,21,22].
The role of B[a]P in carcinogenesis is well established in animal
models, but in humans, there are contradictions. The Interna-
tional Agency for Research on Cancer (IARC) and the
Environmental Protection Agency (EPA) has determined that
B[a]P is probably carcinogenic to humans [9]. B[a]P is thought to
exert its carcinogenic effect via enzymatic activation into reactive
metabolites that are capable of binding to the DNA, leading to
uncontrolled proliferation [23,24]. Apart from it’s carcinogenic
effects, B[a]P has also been shown to be involved in the
development and progression of cardiovascular diseases [24,25].
Owing to its lipophilic nature, B[a]P readily crosses blood-brain
barrier and has also been shown to be accumulated and
metabolized in the brain [26,27] and there have been some
studies that show neurotoxic effects in vivo [28,29,30,31]. Due to
high lipid content, rapid metabolic rate and decreased levels of
antioxidant enzymes in the nervous system, it has been
hypothesized that the nervous system may be highly susceptible
to damage by B[a]P [32], though the exact mechanism that leads
to damage to neurons in the central nervous system (CNS) is yet to
be elucidated. From a behavioral aspect, B[a]P has been shown to
affect neuromuscular, autonomic, sensorimotor and physiological
functions [32] and also affects CNS development and plasticity
[33]. Apart from direct damage, neurons are also susceptible to
inflammatory damages resulting from glial cell activation in the
brain. However, there is little published information relating B[a]P
with modulation of glial cell activation. A study by Weng et al in
2004 had reported elevation of cyclooxygenase-2 in astrocytes
following treatment by B[a]P metabolite to be mediated via
nuclear factor kappa B (NFkB) [34], which suggests modulation of
inflammatory response within the cell. Apart from that, till date
there has been no scientific investigation in this area.
From a global perspective, with ever increasing environmental
pollution levels, PAH contamination poses a serious concern.
Since B[a]P is a potent toxic PAH that causes health hazards, the
present investigation was undertaken to elucidate the underlying
mechanism(s) by which B[a]P exerts its neurotoxic effect. We
hypothesize that the neurotoxic effect of B[a]P, as observed in
earlier studies, is inflammatory in nature, that is mediated by the
activation of glial cells. Microglia being one of the major
inflammatory cells of the CNS, we investigated the changes
undergoing in them, on exposure to B[a]P, and the resulting
changes in neuron-microglia interaction.
Materials and Methods
Ethics Statement
All animal experiments were approved by the institutional
animal ethical review board named ‘‘Institutional Animal and
Ethics Committee of National Brain Research Centre’’. The
animal experiment protocol approval no. is NBRC/IAEC/2008/
46. Animals were handled in strict accordance with good animal
practice as defined by Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), Ministry of
Environment and Forestry, Government of India.
Cell lines and animals
Mouse neuroblastoma Neuro2a (N2a) cells were obtained from
National Centre for Cell Science, Pune, India. Mouse microglial
cell line BV-2 was a kind gift from Dr. Steve Levison, University of
Medicine and Dentistry, New Jersey, USA. All the cell lines were
grown at 37uC in DMEM supplemented with 3.7% sodium bi-
carbonate (NaHCO3), 10% fetal bovine serum and penicillin/
streptomycin. All the reagents related to cell culture were obtained
from Sigma, St. Louis, USA, unless otherwise stated. 4–5 weeks
old BALB/c mice of either sex, chosen randomly from a colony,
were used for all in vivo experiments.
Primary cell culture
Cortical neurons were cultured following a published protocol
[35]. Briefly, cortices of P2 BALB/c mouse pups were dissected
aseptically in calcium-magnesium-free (CMF)-Tyrode solution
following decapitation. The meninges were removed, tissue were
chopped into smaller pieces and collected in CMF-Tyrode. These
were treated with trypsin DNAse and then dissociated in the same
solution by triturating to make a single cell suspension, pelleted
and resuspended in Neurobasal media. Neurobasal media was
supplemented with L-glutamine (2 mM), 30% glucose, 5% fetal
calf serum, 10% horse serum and penicillin–streptomycin. Cells
were plated at a density of 56103 cells/cm2 onto poly-D-lysine-
coated Labtek chamber slides and 96-well plate (Nunc, Roskilde,
Denmark). After 48 h of incubation at 37uC, the serum containing
medium was removed. Cells were incubated with serum free
media for 4 h with antibiotics alone. For experimental treatments,
the resting medium was exchanged for DMEM with N2 and B27
supplements, 25 mM KCl and antibiotics. Arabinoside
(261025 M) was used for the inhibition of astrocyte multiplication.
Primary mixed glial cultures were prepared from P0-2 mouse
brains as described elsewhere [36,37]. Briefly, BALB/c mouse
pups were sacrificed by decapitation and whole brains excluding
cerebelli and olfactory bulbs were isolated. The meninges were
removed, tissues were enzymatically digested using trypsin-
DNAse, mechanically dissociated, and the cell suspension was
passed through 100 mm cell strainers before centrifuging at 400 g
for 7.5 min. After triplicate counts with hemocytometer, cells were
plated into 75-cm2 tissue culture flasks at a density of 26105 viable
cells/cm2 in minimum essential medium (MEM; Invitrogen)
supplemented with 10% fetal bovine serum, 2 mM glutamine,
100 U/100 lg/mL penicillin/streptomycin, and 0.6% glucose.
Table 1. Daily exposure range of humans to benzo[a]pyrene.
Source Exposure amounts
Ingestion of unprocessed grain; charcoal-cooked or smoked meat 0.001–0.9 mg/day [9,14]
Ambient air exposure 0.02–3 mg/day [5,12,13]
Ingestion from contaminated drinking water 0.002–0.12 mg/day [9]
Inhalation of tobacco smoke (depending upon number of cigarettes smoked) 0.5–7.8 mg/day [5]
Occupational exposure levels (via skin) 19.4–25.0 mg/day [3,12,14]
doi:10.1371/journal.pone.0009984.t001
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Media was changed every 3 days after plating. On day 12, the
mixed glial cultures were shaken on an Excella E25 (New
Brunswick Scientific, NJ, USA) orbital shaker at 250 rpm for
60–75 min to dislodge microglial cells. The non-adherent cells
after shaking were plated onto 6-well plates or chamber slides at
86104 viable cells/cm2, and incubated at 37uC for 30 min to
allow microglial cells to adhere. The wells were rinsed extensively
with serum free MEM to eliminate non-adherent cells and debris.
The enriched microglial cultures were fed with 2 mL/well (for 6-
well plates) or 1 mL/well (for 12-well plates) of hormone-
supplemented media that contained 1% fetal bovine serum,
0.66 mg/mL bovine serum albumin (BSA), 100 mg/mL D-biotin,
5 ng/mL insulin, 1 ng/mL selenium, 40 lg/mL iron poor
transferrin, 2 mM glutamine, 15 mM HEPES buffer, and
100 U/100 mg/mL penicillin/streptomycin.
Determination of cell viability
Cell viability was assessed using the [3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium,
inner salt] (MTS; Promega, USA) assay as described earlier [38].
Mouse N2a and BV-2 cells were plated onto separate 96-well
plates at a density of 26104 cells/well in triplicate. Cells were
treated with varying doses of B[a]P (Sigma Aldrich, St. Louis,
USA; 2.5, 5, 10, 20, 30, 40 and 80 mM) for 48 h. Cells marked as
control were treated with DMSO. Twenty microliters of MTS
solution was then added in each well. After 4 h incubation, the
absorbance, reflecting the reduction of MTS by viable cells was
determined at 490 nm. Values were expressed as a percentage
relative to those obtained in controls.
To determine the effect of B[a]P on viability of primary
neurons, cells were isolated as described above and then plated
onto 96-well plates at a density of 26104 cells/well in triplicate.
After the primary neurons developed processes, they were treated
with B[a]P with similar doses, as done with N2a cells. MTS assay
was then performed as described above.
To assess bystander neuronal death by factors released by
microglial cells following B[a]P treatment, BV-2 cells were seeded
in 60 mm culture plates at an density of 56105 cells/plate. After
the cells became confluent, they were incubated with serum free
DMEM for 6 h and then treated with three different doses of
B[a]P (0.02, 0.2 and 2.0 mM) for 3, 12, 24 and 48 h. The
supernatants were collected, filtered and added onto primary
neurons cultured in poly-D-lysine coated 96 well plates. These
cells were then incubated for 48 h following which 20 mL of MTS
solution was added to each well and processed as described above.
Measurement of ROS
The level of ROS produced within cells of control and each
treatment groups were measured by the cell permeable, non-polar,
H2O2-sensitive probe 5(and 6)-chlromethyl-20,70-dichlorodihy-
drofluoresceindiacetate (CM-H2DCFDA; Sigma, USA) by the
method described previously [38]. CM-H2DCFDA diffuses into
cells, where its acetate groups are cleaved by intracellular esterases,
releasing the corresponding dichlorodihydrofluorescein derivative.
Subsequent oxidations of CM-H2DCFDA yields a fluorescent
adduct, dichlorofluorescein that is trapped inside the cell [39].
Briefly, BV-2 cells were plated in five 90-mm plates at a density of
56105 cells/mL (after triplicate counts with a haemocytometer)
and were treated with three different doses of B[a]P (0.02, 0.2 and
2.0 mM) and incubated for 12 and 24 h. The cells were then
harvested by washing with ice-cold PBS and then treated with
5 mM solution of CM-H2DCFDA followed by incubation in dark
at room temperature for 45 min. Cells were then lysed with a
buffer (lysis buffer) containing 1% Triton-X-100, 10 mM Tris–
HCl (pH 8.0), 150 mM NaCl, 0.5% Nonidet P (NP-40), 1 mM
EDTA, 0.2% EGTA, 0.2% sodium orthovanadate, and protease
inhibitor cocktail (Sigma, USA) followed by centrifugation at
13000 rpm for 20 min at 4uC. The protein isolated was then used
to measure the relative fluorescence with the help of Varioskan
Flash multimode reader (Thermo Electron, Finland) at excitation
500 nm and emission 530 nm. The fluorescence intensity of
intracellular CM-H2DCFDA is a linear indicator of the amount of
H2O2 in the cells. A separate cell aliquote, without the CM-
H2DCFDA, was lysed separately to estimate the protein content
by Bradford method. The measured fluorescence intensity of was
normalized to equal concentrations of protein in each sample.
Measurement of Nitiric oxide released
Nitric oxide released from the microglial cells following B[a]P
(0.02, 0.2 and 2.0 mM) treatment was assed using Griess reagent as
described previously [35]. Briefly, BV-2 cells were cultured in 96-
well plates at a density of 26104 cells/ml (after triplicate counts
with a haemocytometer) and were treated as described above.
Following 12 and 24 h incubation post-treatment with B[a]P,
100 mL of Griess reagent (Sigma, St. Louis, USA) was added to
each well and incubated in dark for 15 min. The intensity of the
color developed was estimated at 540 nm with the help of a
Benchmark plus 96-well ELISA plate reader (Biorad, CA, USA).
The amount of nitrite accumulated was calculated (in mM) from a
standard curve constructed with different concentrations of
sodium nitrite.
Cytokine bead array
The BD Mouse Inflammation cytokine bead array (CBA) kits
were used to quantitatively measure cytokine levels in BV-2 cell
culture supernatants and mouse whole-brain lysates. 50 mL of
bead mix containing a population of beads with distinct
fluorescence intensities that have been coated with capture
antibodies for cytokines, and 50 mL of culture supernatant or
whole-brain lysate were incubated together, along with equal
volume of PE-conjugated detection antibodies, for 2 h at room
temperature, in dark. The beads were then washed and
resuspended in 300 mL of supplied 1X wash buffer. The beads
were acquired using Cell Quest Pro Software in FACS Calibur
and analyzed using BD CBA software (Becton Dickinson, San
Diego, CA). Standard curve was prepared by incubating 50 mL of
mouse inflammation standards with 50 mL of bead mix and PE-
conjugated detection antibodies [35].
Immunoblotting
BV-2 cells were plated in 60-mm plates at a density of 105 cells/
mL (after triplicate counts with a haemocytometer) and were
treated as described above. Cells from each treatment groups were
washed twice with ice-cold 1X PBS, and then lysed with lysis
buffer. Protein levels were determined by Bradford method.
Twenty micrograms of each sample was electrophoresed on
polyacrylamide gel and transferred onto a nitrocellulose mem-
brane. After blocking with 7% skimmed milk, the blots were
incubated overnight at 4uC with primary antibodies against iNOS
(Chemicon, USA), SOD-1 (Santa Cruz Biotechnology, CA, USA),
TRX (AB Frontiers, Korea; a kind gift from Dr. Ellora Sen,
NBRC) and phosphoP38 MAP kinase (Cell Signalling, USA) at
1:1000 dilutions. After extensive washes in PBS–Tween, blots were
incubated with appropriate secondary antibodies conjugated with
peroxidase (Vector Laboratories, CA, USA). The blots were again
washed in PBS–Tween and processed for development using
chemiluminescence reagent (Millipore, USA). The images were
captured and analyzed using Chemigenius, Bioimaging System
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(Syngene, Cambridge, UK) [38]. The blots were stripped and
reprobed with anti-b-tubulin (Santa Cruz Biotechnology, USA) to
determine equivalent loading of samples.
Immunofluorescent study of cells and tissues
For immunofluorescent staining of primary neurons, the cells
were plated in poly-D-lysine coated Labtek chamber slide (Labtek,
Roskilde, Denmark) were fixed in 4% paraformaldehyde for
20 min after B[a]P treatment, and then blocked with 5% serum.
The slides were then incubated overnight in humid chamber at
4uC with primary antibodies against beta III tubulin (1:250;
Promega Corporation, Madison, WI, USA) and glial fibrillary
acidic protein (GFAP; 1:500; Dako, Glostrup, Denmark). After
washing with 1X PBS, the slides were incubated with appropriate
secondary antibodies. After final washings the chambers were
removed and slides mounted with DAPI. The slides were observed
under Zeiss Axioplan 2 Fluorescence microscope (Zeiss, Gottin-
gen, Germany).
To show activation of primary microglia following treatment
with B[a]P, cells were seeded onto Labtek chamber slides and
treated with 0.2 mM of B[a]P for 48 h. The cells were then
processed as described above. After blocking the cells were
incubated overnight in humid chamber at 4uC with primary
antibodies against CD11b (1:250; Chemicon, USA), a microglial
marker. On the next day the slides were washed and incubated
with appropriate secondary antibody. After final washes, the
chambers were removed and the slides were mounted with DAPI
and observed under Zeiss Axioplan 2 Fluorescence microscope.
For immunofluorescent staining of intracellular iNOS and
phosphoP38 MAP kinase, primary microglia were cultured and
then seeded onto Labtek chamber slides. Following treatment with
0.2 mM B[a]P treatment for 3 and 12 h, cells were processed for
staining as described above. The cells were incubated overnight,
with primary antibodies against CD11b and iNOS (1:250;
Chemicon, USA) or against CD11b and phosphoP38MAP kinase
(1:250; Cell Signaling, USA), in humid chambers, at 4uC.
Following incubation with appropriate secondary antibodies and
final washes, the chambers were removed, the slides were mounted
with DAPI and observed under Zeiss Axioplan 2 Fluorescence
microscope.
BALB/c mice were intraperitoneally (i.p) injected with B[a]P at
doses of 100 mg, 1 mg, and 10 mg per kg body weight, for 4 days.
Control animals were injected with DMSO. Animals from control
and B[a]P treated groups were sacrificed after 4 days of treatment,
after anesthetizing them with ketamine hydrochloride, adminis-
tered i.p at a dose of 40 mg/kg body weight. After repeated
transcardial perfusion with ice cold 1X PBS, the brains were
excised and processed for cryostat sectioning. To label activated
microglia and activated astrocytes, 20 micron thick sections were
incubated overnight at 4uC with rabbit anti-Iba-1 (Wako, Osaka,
Japan) and rabbit anti-glial fibrillary acidic protein (GFAP) (Dako,
Glostrup, Denmark), respectively at dilutions of 1:500. After
washes, slides were incubated with appropriate secondary
antibodies conjugated with fluorescein (Vector Laboratories, CA,
USA) and following final washes, sections were mounted with
DAPI. The slides were observed under Zeiss Apotome microscope
and Zeiss Axioplan 2 fluorescence microscope (Zeiss, Gottingen,
Germany), respectively.
Statistical analysis
Statistical analysis was performed using SIGMASTAT software
(SPSS Inc., Chicago, IL, USA). Data were compared between
groups using one-way analysis of variance followed by Fisher’s post
hoc test. Differences upto p,0.05 were considered significant.
Results
B[a]P does not cause cytotoxicity to primary neurons or
neuronal cell lines, directly
Earlier reports have indicated that B[a]P can be transported and
metabolized in the brain [26,27], apart from other tissues in the body.
However, whether B[a]P causes direct neuronal death has not been
clearly described. The dose response study using varying doses of
B[a]P (as low as 2.5 mM to as high as 80 mM) on murine
neuroblastoma cell line (N2a) and murine primary cortical neurons,
seeded in 96-well culture plates, revealed that the cell viability in all
Figure 1. B[a]P treatment does not cause cytotoxicity in murine neuroblastoma cell line, primary cortical neurons or microglial
cells. Mouse neuroblastoma Neuro2a (N2a) cells were plated onto 96-well plates, in triplicates, and treated with varying doses of B[a]P. After 48 h
incubation, MTS assay was performed that showed that there was no significant amount of cell death in any B[a]P treated groups (A). Similar
experiment, when repeated on murine primary cortical neuron, grown on poly-D-lysine coated 96-well plate in triplicates, showed similar results (B).
Data represents Mean 6 SD of three independent experiments. Murine microglial cell (BV-2), cultured in 96-well plates in triplicates, were treated
with varying doses of B[a]P for 48 h. MTS assay was then performed to evaluate cell viability. Results show that there was no significant difference in
viability of B[a]P treated microglial cells when compared to control cells (C).
doi:10.1371/journal.pone.0009984.g001
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treatment groups after 48 h of B[a]P administration was 100620%.
The changes in viability, as shown by the MTS assay, were not found
to be significantly different from the control cells (Fig. 1A & B). Light
microscopic images as well of immunofluorescent staining of control
and 80 mMB[a]P treated primary neurons did not show any marked
difference (Fig. S1A & B).
Treatment with B[a]P leads to activation of murine
microglial cells but no cytotoxicity
Microglia are the brains’ defense against external pathogens as
well as help in the internal clearance of debris. Like neurons or
neuronal cell lines, microglia seems to be immune to cytotoxic
damage following B[a]P treatment. MTS assay performed on
Figure 2. Intracellular ROS is increased after B[a]P treatment and that also affects stress protein levels. BV-2 cells were treated with
0.02 mM, 0.2 mM and 2.0 mM of B[a]P and incubated for 12 h and 24 h. Following incubation, cells were collected and treated with 5 mM solution of
CM-H2DCFDA followed by incubation in dark at room temperature for 45 min. Cells were then lysed and centrifuged at 13000 rpm for 20 min at 4uC.
Supernatant obtained was used for fluorimetric estimation of ROS using a Varioskan Flash multimode reader. Results show that intracellular ROS
levels were significantly elevated in all B[a]P treated groups at either time points except in the 0.2 mM group, after 12 h treatment. The ROS level was
significantly higher in 0.2 mM and 2.0 mM groups as compared to 0.02 mM group, 12 h post treatment. After 24 h of treatment, it was observed that
ROS levels in 2.0 mM group was significantly higher than that in 0.2 mM group; moreover ROS level in 0.2 mM group was higher than 0.02 mM group.
Data is represented as Mean6 SD of fold changes over control from triplicate sets of experiments. * p,0.01 for all treatment groups when compared
to respective time matched controls; # p,0.01 for 0.2 mM and 2.0 mM groups as compared to 0.02 mM group, 12 h post treatment; ‘ p,0.01 for
0.2 mM group as compared to 0.02 mM group in 24 h post treatment sample; d p,0.01 for 2.0 mM group as compared to 0.2 mM group in 24 h post
treatment sample (A). Levels of intracellular stress proteins- SOD-1 and TRX- following treatment with varying doses of B[a]P were determined by
western blotting (B). Results show that after 3 h of B[a]P treatment SOD-1 levels were significantly higher in both 0.2 mM and 2.0 mM groups as when
compared to the control. However, SOD-1 levels were significantly decreased in 12 h and 24 h post treatment samples, irrespective of the dose. It
was also observed that ROS levels were comparatively higher in 2.0 mM groups than in 0.2 mM groups in both 12 h and 24 h samples (C). TRX levels
were found to be significantly decreased in all B[a]P treated groups except in 2.0 mM group, 24 h post infection. TRX levels were also, significantly
higher in 2.0 mM group as compared to 0.2 mM group in 3 h and 24 h post infection samples (D). Data is represented as Mean 6 SD of fold changes
over control from triplicate sets of experiments. * p,0.01 for 0.2 mM and 2.0 mM B[a]P treated groups when compared to control; ** p,0.01 for
0.2 mM and 2.0 mM B[a]P treated groups when compared to control; #p,0.01 for 2.0 mM group as compared to 0.2 mM group.
doi:10.1371/journal.pone.0009984.g002
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Figure 3. B[a]P treatment causes elevated NO release from microglia and also modulates intracellular iNOS levels. BV-2 cells were
were treated with B[a]P at doses of 0.02 mM, 0.2 mM and 2.0 mM for 12 h and 24 h. NO released by the cells were then estimated using Greiss reagent
from the culture supernatants. Results show that NO released from B[a]P treated microglia was significantly higher than control microglia that were
B[a]P Causes Brain Damage
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B[a]P treated microglial cell line showed clearly that there was no
significant cell death (Fig. 1C). We found that following treatment
with B[a]P there was microglial activation. Light microscopic
imaging of BV-2 showed that even after 48 h of incubation, B[a]P
treated cells showed morphological signs of activation (Fig. S1C).
Immunofluorescent staining of B[a]P treated primary microglia
for CD11b, a microglial marker, also showed that the cells indeed
showed an activated morphology (Fig. S1D).
B[a]P causes elevation of ROS production in microglial
cells and modulates intracellular stress protein levels
Microglial activation results in elevation of intracellular ROS
levels in them [40]. To see whether B[a]P treatment affects
intracellular ROS levels, BV-2 cells were treated with 0.02 mM,
0.2 mM, 2.0 mM B[a]P for 12 h and 24 h. ROS was estimated
fluorimetrically by addition of the cell permeable, non-polar,
H2O2-sensitive probe CM-H2DCFDA. It was observed that 12 h
post treatment with B[a]P, ROS levels were significantly increased
in 0.2 mM and 2.0 mM treated groups (p,0.01); after 24 h
treatment significant increase was observed in all three treatment
groups when compared to control (p,0.01). In 24 h treated
samples the ROS levels in 0.2 mM group was significantly higher
than 0.02 mM treated sample, and that in 2.0 mM group was
significantly higher than 0.2 mM group (p,0.01) (Fig. 2A).
Intracellular level of superoxide dismutase 1 (SOD-1) was found
to be significantly elevated after 3 h treatment with 0.2 mM and
2.0 mM B[a]P, when compared to time matched, control cells
(p,0.01). SOD-1 was found to be slightly elevated in the 0.2 mM
B[a]P treated sample than the 2.0 mM B[a]P sample, though this
was not statistically significant. However in 12 h and 24 h post
treatment sample, SOD-1 levels were found to be significantly
decreased than control in all B[a]P treated groups (p,0.01). Also,
it was observed that in 12 h and 24 h post treatment samples,
SOD-1 level was significantly greater in 2.0 mM than in 0.2 mM
group (p,0.01) (Fig. 2B & C). Thioredoxin (TRX) levels were
found to be significantly decreased than control in all B[a]P
treated groups at all time points except 2.0 mM group 24 h post
infection (p,0.01). Also TRX levels were significantly higher in
2.0 mM group as compared to 0.2 mM group in 3 h and 24 h post
infection samples (p,0.01) (Fig. 2B & D).
B[a]P causes increased release of nitric oxide from
microglial cells and modulates intracellular inducible
nitric oxide synthase levels
Activated microglia are known to produce nitric oxide (NO)
that is capable of causing neuronal damage [41]. We found that
upon B[a]P treatment, there was significantly increased NO
release from BV-2 cells after 12 or 24 h of treatment when
compared to untreated time matched controls (p,0.01). More-
over, it was observed that fold increase of NO released over
control after 24 h treatment with B[a]P, was significantly higher,
when compared to 12 h treatment groups (p,0.01). In 24 h post
treatment group, it was observed that the increase in NO release
seemed to be dose dependent. NO released from 0.2 mM group
was significantly higher (,1.7 fold) than 0.02 mM group, whereas
that from 2.0 mM group was significantly higher (,2.3 fold) than
0.2 mM group (p,0.01) (Fig. 3A).
Immunocytochemical study performed to observe intracellular
inducible nitric oxide synthase (iNOS) levels following B[a]P
treatment were achieved by staining primary microglia with anti-
iNOS antibody. Primary microglia were cultured in chamber
slides and treated with 0.2 mM B[a]P for 3 h and 12 h. Time
matched controls were treated with DMSO. Co-staining with anti-
iNOS and anti-CD11b antibody showed that after 3 h of
treatment, there was expression of iNOS within the microglia.
After 12 h treatment, the expression was visibly higher than that
observed in 3 h post treatment cells (Fig. 3B).
Intracellular phosphoP38 MAP kinase levels are
modulated as a result of B[a]P treatment
Protein harvested from BV-2 cells after 3 h, 12 h and 24 h
treatment with 0.2 mM and 2.0 mM B[a]P were processed for
immunoblotting to detect intracellular level of phosphoP38 MAP
kinase. The results show that phosphoP38 MAP kinase levels were
significantly elevated in 3 h post treatment groups and also in
0.2 mM treated group after 12 h (p,0.01). After 24 h, there was
no significant difference in the phosphoP38 MAP kinase levels in
either B[a]P treated group when compared to time matched
control. However, it was observed that phosphoP38 MAP kinase
level in 0.2 mM B[a]P treated group after 12 h, was significantly
decreased as compared to that in 3 h post treatment group
(p,0.05). Similarly, phosphoP38 MAP kinase level in 0.2 mM
B[a]P treated group after 24 h, was significantly decreased as
compared to that in 12 h post treatment group (p,0.01).
PhosphoP38 MAP kinase level was also significantly reduced in
24 h post treatment 2.0 mM group when compared to 3 h and
12 h post treatment groups of the same concentration (p,0.01)
(Fig. 4A & B).
Immunofluorescent staining to detect intracellular phosphoP38
MAP kinase after B[a]P treatment was also carried out on primary
microglia. Cells cultured on chamber slides were treated with
0.2 mM B[a]P for 3 h and 12 h following which they were fixed
with 4% paraformaldehyde, and stained with anti-phosphoP38
MAP kinase antibody. The results show that upon treatment with
B[a]P there was an increased intracellular expression of phos-
phoP38 MAP kinase. This was also prominently observed after
12 h treatment. (Fig. 4C).
B[a]P treated microglia secrete proinflammatory
cytokines
BV-2 were cultured in 60 mm plates and were treated with
varying doses of B[a]P for 3 h, 12 h, and 24 h. CBA was
performed using kits with the culture supernatants to quantitate
treated with DMSO only. The NO released from 0.2 mM and 2.0 mM groups were significantly higher than 0.02 mM groups after both 12 h and 24 h of
treatment. Fold increase of NO release from B[a]P treated microglia over control was greater after 24 h as compared to 12 h. Results are Mean 6 SD
of fold changes over control from triplicate sets of experiments. * p,0.01 for all treatment groups when compared to respective controls; # p,0.01
for 0.2 mM and 2.0 mM B[a]P treated group when compared to 0.02 mM B[a]P group, 3 h post treatment; ‘ p,0.01 for fold increases after 24 h when
compared to fold increases after 12 h treatment in all groups; d p,0.01 for 0.2 mM B[a]P treated group when compared to 0.02 mM B[a]P treated
group; e p,0.01 for 2.0 mM B[a]P treated group when compared to 0.2 mM B[a]P treated group (A).To assess whether iNOS expression was altered
within microglial cells following B[a]P treatment, primary microglia cultured in chamber slides were treated with 0.2 mM B[a]P for 3 h and 12 h. Time
matched control cells received DMSO. The cells were costained for CD11b, a microglial marker and iNOS and images were captured in a Zeiss
Axioplan 2 fluorescence microscope. The images show that there is increased expression of iNOS following B[a]P treatment. This increase was more
prominent after 12 h as compared to 3 h treatment (B). White arrow denotes cells in which activation is visibly prominent. Images are representative
of triplicate sets. Magnification is 206; scale bar corresponds to 50 m.
doi:10.1371/journal.pone.0009984.g003
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the amount of cytokines released into the supernatant from the
cells. The MCP-1 level was found to be significantly increased
than control, only after treatment with 0.2 mM B[a]P for 3 h
(p,0.01). Similar result was also observed after 12 h treatment,
but after 24 h, MCP-1 levels were found to increase significantly in
all B[a]P treated groups when compared to their time matched
control (p,0.01). However, in this case also, the 0.2 mM treated
group showed maximal release of MCP-1 (Fig. 5A). TNF-a levels
showed no significant difference in 0.02 mM and 0.2 mM B[a]P
treated groups after 3 h of treatment, but in the 2.0 mM treated
group, there was a significant increase (p,0.01). After 12 h of
treatment, the 0.2 mM and 2.0 mM groups showed significant
increase in TNF-a when compared to control and also when
compared to 0.02 mM treated group (p,0.01). Similar results were
obtained after 24 h treatment (Fig. 5B). IL-6 levels were not found
to be significantly different in any B[a]P treated group, after 3 h of
treatment. After 12 h, the 0.2 mM and 2.0 mM B[a]P treated
groups showed significant increase in IL-6 secretion when
compared to control cells, and also when compared to 0.02 mM
treated group (p,0.01). Also, the IL-6 level in 2.0 mM group was
found to be significantly lesser than that observed in 0.2 mM group
(p,0.01). After 24 h, IL-6 levels were found to be significantly
elevated in all B[a]P treated groups (p,0.01). However, the IL-6
level in 2.0 mM group was found to be significantly lesser than that
observed in 0.2 mM group (p,0.01) (Fig. 5C).
Activation of microglia by B[a]P treatment leads to
bystander neuronal death
Activated microglia is known to produce an array of
proinflammatory mediators that are in turn deleterious for
surrounding neurons in the CNS [9,42,43]. To check whether
B[a]P causes bystander neuronal death by activating microglia, we
treated murine microglial cell BV-2 with varying doses of B[a]P,
viz. 0.02 mM, 0.2 mM and 2.0 mM, for 3 h, 12 h, 24 h and 48 h.
The control comprised of culture supernatants from time matched
DMSO-treated BV-2 cells. The culture supernatants were
collected and stored at 220uC after each time period. After
collection of the 48 h sample, filtered aliquots of these superna-
tants were added on mouse primary cortical neurons that had
been cultured in triplicates, in poly-D-lysine coated 96-well plates
followed by incubation for 48 h. MTS assay performed to
determine cell viability post treatment with B[a]P treated BV-2
Figure 4. B[a]P treatment results in modulation of intracellular phosphop38 MAP kinase. Western blotting was performed with protein
harvested from BV-2 cells after 3 h, 12 h and 24 h treatment with 0.2 mM and 2.0 mM B[a]P (A). PhosphoP38 MAP kinase levels were significantly
elevated in 3 h post treatment groups and also in 0.2 mM treated group after 12 h. After 24 h, there was no significant difference in the phosphoP38
MAP kinase levels in either B[a]P treated group when compared to time matched control. However, it was observed that phosphoP38 MAP kinase
level in 0.2 mM B[a]P treated group after 12 h, was significantly decreased as compared to that in 3 h post treatment group. Similarly, phosphoP38
MAP kinase level in 0.2 mM B[a]P treated group after 24 h, was significantly decreased as compared to that in 12 h post treatment group.
PhosphoP38 MAP kinase level was also significantly reduced in 24 h post treatment 2.0 mM group when compared to 3 h and 12 h post treatment
groups of the same concentration (B). Data is represented as Mean6 SD of fold changes over control from triplicate sets of experiments. * p,0.01 for
all groups as compared to control; # p,0.05 for 12 h 0.2 mM group as compared to 3 h 0.2 mM group; ## p,0.01 for 24 h 0.2 mM group as
compared to 12 h 0.2 mM group; d p,0.01 for 24 h 2.0 mM group as compared to 12 h 2.0 mM group. Primary microglia were stained with anti-
phosphoP38 MAP kinase and anti-CD 11b antibodies, after 3 h and 12 h B[a]P treatment. The results show that upon treatment with B[a]P there was
an increased intracellular expression of phosphoP38 MAP kinase. This was also observed after 12 h treatment. Moreover, in the 12 h treated cells, the
phosphoP38 MAP kinase’s fluorescent signals seemed to be localized towards the nucleus (C). White arrow denotes cells in which activation is visibly
prominent. Images are representative of triplicate sets. Magnification is 206; scale bar corresponds to 50 m.
doi:10.1371/journal.pone.0009984.g004
Figure 5. Proinflammatory cytokine levels are increased in culture supernatants following B[a]P treatment. Quantitative estimation of
proinflammatory cytokines released in the culture media by B[a]P-treated BV-2 cells were carried out with the help of BD CBA kits. Data was acquired
and analyzed in BD FACS calibur instrument with the help of Cell Quest Pro software. MCP-1 was was found to be significantly increased than control,
only after treatment with 0.2 mM B[a]P in 3 h and 12 h post treatment samples. In 24 h samples, all groups showed significantly increased MCP-1
level than control (A). TNF-a was found to be increased significantly in 2.0 mM B[a]P treated sample after 3 h and in 0.2 mM and 2.0 mM B[a]P treated
samples after 12 h and 24 h when compared to control and 0.02 mM treated sample (B). IL-6 levels were not found to be significantly different in any
B[a]P treated group, after 3 h of treatment. After 12 h, the 0.2 mM and 2.0 mM groups showed significant increase in IL-6 when compared to control
and also when compared to 0.02 mM treated. IL-6 level in 2.0 mM group was found to be significantly lesser than that observed in 0.2 mM group. After
24 h, IL-6 levels were found to be significantly elevated in all B[a]P treated groups. However, the IL-6 level in 2.0 mM group was found to be
significantly lesser than that observed in 0.2 mM group (p,0.01) (C). Data is represented as Mean 6 SD of fold changes over control from triplicate
sets of experiments. * p,0.01 for significant increases over control; # P,0.01 for significant increases over 0.02 mM groups; ‘ p,0.01 for 2.0 mM as
compared to 0.2 mM treated group.
doi:10.1371/journal.pone.0009984.g005
B[a]P Causes Brain Damage
PLoS ONE | www.plosone.org 9 April 2010 | Volume 5 | Issue 4 | e9984
supernatants. Results show that in the cells on which 3 h culture
supernatant was added, there was no significant cell death in
0.2 mM and 2.0 mM treatment groups but the 0.02 mM treated
groups showed increased viability (p,0.05) (Fig. 6A). Primary
cortical neurons on which 12 h post treatment culture superna-
tants were added showed significantly reduced viability in all
groups, when compared to control (p,0.01). The viability of
primary neurons on which 0.2 mM B[a]P treated BV-2 culture
supernatant was added showed a significantly reduced viability
when compared to 0.02 mM treated group (p,0.01); similarly
2.0 mM group showed lesser viability than 0.2 mM treated group
(p,0.01) (Fig. 6B). In primary neurons on which 24 h post
treatment supernatants were added, all groups showed significant-
ly reduced viability than the control (p,0.01), however there were
no differences between 0.02 mM, 0.2 mM and 2.0 mM treated
groups (Fig. 6C). Similar observations were recorded in primary
neurons on which 48 post treatment supernatants were added
(Fig. 6D).
Figure 6. Bystander neuronal death caused by B[a]P treated microglia. To assess whether B[a]P treated microglia causes bystander neuronal
death in vitro, BV-2 cells were treated with 0.02 mM, 0.2 mM and 2.0 mM of B[a]P for 3, 12, 24 and 48 h. After each time point the culture supernatant
were collected form each treatment group, filtered and stored at 220uC. Time matched controls were simultaneously maintained that were treated
with DMSO. Primary cortical neurons were then treated with these culture supernatants and incubated for 48 h, followed by MTS assay. Results show
that on addition of 3 h post treatment supernatants, there was no significant difference in cell viability in 0.2 mM and 2.0 mM groups, when compared
to control. However, the cells in 0.02 mM treatment group showed an increased viability (A). On addition of 12 h post treatment supernatants, there
was significant reduction of cell viability in all treatment groups as compared to the group that was treated only with control. Moreover, it was
observed that the viability of 0.2 mM group was significantly lesser than that in 0.02 mM group. Similarly the viability in 2.0 mM group was significantly
lesser than in 0.2 mM group (B). After addition of 24 h post treatment supernatant on primary neurons, the viability was found to be significantly
decreased in all treatment groups when compared to control, but there was no significant difference between the viability of the treatment groups
(C). Addition of 48 h post treatment supernatants on primary neurons also resulted in significant decrease of cell viability as compared to control, but
there was no significant difference between the B[a]P treated groups (D).Data represented as Mean 6 SD of three independent experiments;
# p,0.01 for 0.02 mM treatment group when compared to control; * p,0.01 for all treatment groups compared to control; ** p,0.01 for 0.2 mM
treatment group when compared to 0.02 mM treatment group; ‘ p,0.01 for 2.0 mM treatment group when compared to 0.2 mM treatment group.
doi:10.1371/journal.pone.0009984.g006
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B[a]P causes upregulation of proinflammatory cytokines
in brain in vivo
To find out whether B[a]P also causes inflammatory changes in
vivo, we administered B[a]P at doses of 100 mg, 1 mg and 10 mg
per kg body weight (henceforth referred as 100 mg, 1 mg and
10 mg treated groups), intraperitoneally, to BALB/c mice for 4
consecutive days. Proinflammatory cytokine levels in brain tissue
homogenates were estimated using CBA kits. Results show that
after 4 days of treatment there was an increased MCP-1 level in
1 mg and 10 mg B[a]P treated groups (p,0.01) when compared
to either control or 100 mg treated groups. Moreover, MCP-1 was
significantly higher in 10 mg group, when compared to 1 mg
(p,0.01) (Fig. 7A). TNF-a levels were significantly increased in all
B[a]P treated groups when compared to control (p,0.01). Also,
TNF-a level in 1 mg and 10 mg groups was significantly higher
than 100 mg group (p,0.001) (Fig. 7B). IL-6 level was found to be
elevated in all B[a]P treated groups when compared against
control (p,0.01). The level in 1 mg and 10 mg group was
significantly higher than that in 100 mg group (p,0.01); also it was
significantly higher in 10 mg group when compared to 1 mg
group (p,0.01) (Fig. 7C).
B[a]P causes microglial activation and astrogliosis in the
brain
Microglia and astrocytes have both been reported to be
involved with inflammatory reactions taking place within the
brain [44,45]. To check whether B[a]P treatment causes activation
of microglia or astrocytes, 20 m thick cryostat sections of brain
from control and B[a]P treated animals were analyzed immuno-
histochemically for Iba-1, a marker for microglia and GFAP, a
marker for astrocytes. Images show that after 4 day treatment
there was microglial activation in all B[a]P treated groups (Fig. 8D–
L). Robust changes in morphology of the microglia were observed
in 1 mg and 10 mg treated groups (Fig. 8G–L). Astrogliosis was
also observed in all B[a]P treated groups (Fig. 8P–X); however in
1 mg and 10 mg groups, the change in morphology was
prominent (Fig. 8S–X). The number of astrocytes was also found
to be highest in 10 mg treated group, if compared with all other
treatment groups. The figures represent cryosections of a mouse
brain from each group as a representative of six animals from each
group.
Discussion
From an ecological aspect, B[a]P as a pollutant has been under
investigation for quite some time [13,46,47]. It is relevant in
environmental and occupational settings where specific popula-
tions are chronically exposed to B[a]P that is released from
hazardous waste sites, or via food, water or tobacco, or during
direct occupational exposures. B[a]P has been shown to be
metabolized and accumulated in hepatic cells [48] and has also
been found in the brain at least after 24 h post administration
[27]. Investigations in the past has reported neuronal death
following B[a]P administration [28,29,30,31], though the actual
mechanism by which the death occurs is unknown. In this study,
using neuroblastoma cell lines and primary cortical neurons, it was
found that even after using B[a]P at doses as high as 80 mM, there
was no significant decrease in cell viability. Microscopic imaging
also failed to demonstrate any evidence of morphological changes
of the cells. Taken together, these results clearly show that doses of
B[a]P up to 80 mM are not directly toxic to neurons. As the cells
had been incubated with B[a]P for upto 48 h, it can be safely
assumed that whatever metabolite of B[a]P had been formed
within the cells, was also not cytotoxic to neurons. Thus, ruling out
the direct damage to neurons due to toxicity, the other significant
way by which neuronal death can occur is due to the generation of
an inflammatory milieu within the brain. Microglia are resident
macrophages of the CNS whose overexpression or dysregulation is
instrumental in generating inflammatory response within the
brain. We suspected that changes in microglia due to administra-
tion of B[a]P may be a contributing factor that is responsible
neurotoxicity. To test this hypothesis, we performed survivality
assay after addition of B[a]P to murine microglial cell line BV-2, in
same doses as applied to neuroblastoma cells or primary neurons,
and observed no significant decreases in cell survivality. When
Figure 7. Treatment with B[a]P causes elevation of proinflammatory cytokines in the brain. Mice were administered 100 mg, 1 mg and
10 mg of B[a]P, intraperitoneally for 4 consecutive days and then sacrificed. The brain was excised out and homogenized. The homogenates were
used for determination of proinflammatory cytokine content using CBA kit. Results show that MCP-1 was increased in 1 mg and 10 mg treated
groups as compared to control. Also, the MCP-1 level in 10 mg group was higher than that in 1 mg group (A). TNF-a levels were significantly
increased after B[a]P administration in all groups, as compared to control. TNF-a level in 1 mg and 10 mg groups were also significantly higher than
100 mg group (B). IL-6 levels showed a significant increase in all B[a]P treated groups compared to control. IL-6 level in 1 mg and 10 mg group was
significantly higher than that in 100 mg group; also it was significantly higher in 10 mg group when compared to 1 mg group (C). Data is represented
as Mean 6 SD of fold changes over control from six animals of each group. * p,0.01 for changes over control; # p,0.01 for changes over 100 mg
group; ‘ for changes over 1 mg group.
doi:10.1371/journal.pone.0009984.g007
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observed under microscope, the microglia seemed to be activated
(data not shown). The doses of B[a]P used for survivality assays,
had been chosen at random, to test a wide range. However, for the
study to achieve physiological significance, such doses had to be
used that would seem relevant to the real life scenario. The lowest
detectable concentration of B[a]P common to human experience,
for statistically significant mutations in human cells, has been
found to be 0.02 mM [49]. We chose this value as our lowest dose
and two other subsequent doses that are 10-folds and 100-folds
higher, (0.2 mM and 2.0 mM respectively), for the in vitro
experiments. On application of these doses, it was found that
there were clear morphological signs of activation in BV-2. On
treating primary microglia with 0.2 mM B[a]P for 48 h, the cells
were found to assume an ameboid morphology that is also
indicative of its activated state.
The intracellular ROS levels are an important characteristic in
the cellular responses to external stress. Increase in ROS levels
initiates various responses within the cell, including damage to
proteins, DNA and lipid [50]. When intracellular ROS was
measured from the microglia, after treatment with varying doses of
B[a]P for different time periods, we found that there was
significant increase. Correspondingly, SOD-1 and TRX levels
were found to be decreased within the microglia. SOD-1 has been
reported to ameliorate the oxidative stress generated by wide array
of causes and also protects the cells from stress-induced apoptosis.
However, we see that B[a]P induced oxidative stress is not being
countered by SOD-1. TRX is also another important antioxidant
component within the cell that is necessary to ameliorate elevated
ROS. TRX scavenges ROS by itself and in cooperation with
peroxiredoxin and also plays a crucial role in the redox regulation
of transcription factors for the expression of various genes. TRX
levels were also found to be reduced after B[a]P treatment. Thus it
seems that the intracellular antioxidant machinery of the cell is not
capable of countering the oxidative stress generated due to B[a]P.
NO produced from the B[a]P treated microglia was found to be
increased substantially than untreated cells. NO, a major signaling
molecule has been shown to induce oxidative stress and trigger
apoptosis in neuronal cells [51]. The magnitude of NO release was
found to be greatly increased after 12 h and 24 h post treatment
with B[a]P. NO released from these microglia can thus act on
neurons to initiate killing. We also found that intracellular iNOS
expression was also increased correspondingly. Primary microglia,
Figure 8. Activation of microglia and astrogliosis in vivo due to B[a]P treatment. Microglial activation following B[a]P treatment was
observed by staining the cryosections for Iba-1. The figure clearly show that B[a]P treatment successfully caused microglial activation (D–L), as
compared to control (A–C), though it was more prominent in 1 mg and 10 mg treated animals (G–I & J–L). Astrogliosis was also observed after 4 day
treatment with B[a]P, if compared with control (M–O). In the 1 mg (S–U) and 10 mg (V–X) treated groups the morphology of the activated cells were
more robust than compared to 100 mg treated group (P–R). The figures represent cryosections of a mouse brain of each group as a representative of
six animals from each group. Images of sections stained for Iba-1 were acquired using a Zeiss Apotome microscope, while those that were stained for
GFAP were acquired using a Zeiss Axioplan 2 fluorescence microscope. Magnification is 206; scale bars correspond to 50 m.
doi:10.1371/journal.pone.0009984.g008
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when stained for iNOS, showed increased expression of iNOS
after 12 h which suggests that B[a]P treatment causes its
upregulation. Thus, these data clearly shows that following
B[a]P treatment, iNOS is induced within microglia that results
in increased production of NO from the cells.
The p38 MAPK pathway has been shown to be activated by
ROS [52]. Studies have also shown that once p38 MAPK pathway
is activated, it is capable of damaging antioxidative system that
further increases intracellular ROS levels. P38 MAPK pathway is
also known to be involved in the production of various cytokines,
in response to stress. Thus, intracellular levels of phosphoP38
MAPK were found to be elevated within the microglia following
treatment with B[a]P for 3 h, 12 h and 24 h. Interestingly, it was
also observed that the phosphoP38 MAPK, though higher than
untreated cells, tends to decrease as time progresses. This may be
explained by the fact that nuclear translocation of phosphoP38
MAPK occurs to initiate transcription for the synthesis of
proinflammatory cytokines, though further studies are required
to substantiate this aspect.
The levels of proinflammatoy cytokines such as MCP-1, TNF-a
and IL-6 were estimated from microglial culture supernatants after
treatment with B[a]P for different time periods. A general increase in
the secretion of the cytokines from 12 h onwards was observed that
persisted even after 24 h, but no significant difference was found after
48 h (data not shown). After 3 h treatment, only 0.2 mM and 2.0 mM
treated groups showed some difference in case of MCP-1 and TNF-
a, respectively. This is plausible as the cellular machinery needs time
to produce these cytokines and subsequently release them. Also,
taking into consideration the time factor, after 48 h we failed to find
any significant difference in the cytokines levels. Interestingly, we also
found that treatment with the 0.2 mMdose showed maximal cytokine
(MCP-1 and IL-6) production from the cells. The 0.2 mM doses may
be ideal for optimal response from the microglia, but it would not be
prudent to come to such conclusions without further studies and thus,
this phenomenon, currently remains enigmatic. IL-6 is known to
induce neuronal death by excessive activation of NMDA receptors
[53]. TNF-a induces inflammatory reactions and can induce death
signaling via receptors present on neurons [54] or may do so by
abnormal AMPA receptor trafficking [55]. MCP-1 does not directly
affect neuronal death, however it has been shown to be associated
with microglial activation [56] leading to bystander neuronal death.
Thus, the inflammatory milieu created by the secretion of these
proinflammatory cytokines could be detrimental to neurons.
On the basis of above observations, we were interested to see
whether culture supernatants of B[a]P treated microglia, could
actually affect neuronal survivality. On addition of the superna-
tants onto primary neurons, it was seen that there was significant
reduction of neuronal viability. This effect was prominent from the
12th hour post treatment samples. This shows that following
treatment with B[a]P, the neurotoxic factors that are actually
responsible for killing the neurons, have accumulated in sufficient
amount after 12 h of treatment. This effect was observed till the
addition of 48 h post treatment supernatant, indicating that the
factors that are responsible for the death of the neurons, are being
secreted till that time. Thus the combination of ROS, NO and
proinflammatory cytokines seems to act in a synergistic way to
cause bystander death to neurons.
In vivo experiments showed that after 4 days of B[a]P treatment,
proinflammatory cytokine levels in brain were found to be
significantly elevated. MCP-1, IL-6 and TNF-a levels were found
to be increased in a dose dependent manner, indicating microglial
activation in the brain following B[a]P administration. To confirm
this assumption, brain sections were stained for activated microglia
which were found to be present prominently in 1 mg and 10 mg
B[a]P treated animals and also to a lesser extent in 100 mg treated
group. Similarly, astrogliosis was also observed in all three B[a]P
treated groups.
In conclusion it may be said that B[a]P induces microglial
activation by increasing intracellular ROS levels, down regulating
antioxidant proteins and activating p38MAP kinase pathway. This
leads to release of proinflammatory cytokines and NO which in
turn initiates an inflammatory cascade in the CNS, resulting in
bystander neuronal death (Fig. S2). In this study, we have shown
for the first time the role of B[a]P in inducing neuroinflammation
in the CNS and its possible outcome. Increasing environmental
pollution levels have led us to believe that presence of PAHs
should also increase simultaneously. Thus from today’s perspective
this study is assumes significance as this study involves a potent
environmental pollutant, B[a]P.
Supporting Information
Figure S1 Photomicrographs showing effect of B[a]P treatment
on N2a, primary neurons, BV-2 and primary microglia. Light
microscopic images of primary cortical neurons, grown in poly-D-
lysine coated chamber slides that were treated with 80 mM of
B[a]P, did not reveal any significant morphological alterations
when compared to control (A). To confirm this finding,
immunofluorescent staining of the B[a]P treated primary neurons
were done. The slides were stained for beta III tubulin, a primary
neuronal marker, and glial acidic fibrilary protein (GFAP), a
marker for activated astrocytes, followed by mounting with DAPI.
The image shows that no significant change can be visualized in
the B[a]P treated neurons when compared to control (B). The
scale bars correspond to 50 m and magnification is 206. Light
microscopic images of BV-2 after treatment with varying doses of
B[a]P for 48 h shows morphological signs of activation at all three
doses (C). To see whether primary microglia also became activated
due to B[a]P, cells were culture and then seeded onto chamber
slides and treated with 0.2 mM B[a]P for 48 h. The slides were
then processed to be stained with anti-CD11b antibody and
mounted with DAPI. Images were captured using Zeiss Axioplan 2
fluorescence microscope. Figure S1D clearly shows morphological
difference between B[a]P treated and untreated cells. Scale bar
correspond to 50 m in both (C) and (D). Magnification is 206 in
both figures.
Found at: doi:10.1371/journal.pone.0009984.s001 (2.93 MB TIF)
Figure S2 Schematic diagram showing the proposed mechanism
of action of B[a]P. B[a]P causes activation of microglia by
elevating intracellular ROS levels and subsequently decreases
antioxidant protein (SOD-1 & TRX) levels. Expression of iNOS is
increased in B[a]P treated microglia that leads to increased
production and release of NO from them. The p38MAP kinase
pathway is also upregulated by B[a]P. The proinflammatory
cytokines and NO released results in generation of an inflamma-
tory milieu that is detrimental for neurons.
Found at: doi:10.1371/journal.pone.0009984.s002 (0.09 MB TIF)
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